PRESS RELEASES

Akur8 and Xceedance Announce Strategic Partnership

Delivery of state-of-the-art pricing solutions to insurers is a key objective of the new relationship.

PARIS and BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) — Akur8 and Xceedance today announced a strategic partnership to deliver best-in-class actuarial and analytics solutions to insurance organizations.

The partnership between Xceedance and Akur8 provides an opportunity for insurers to gather extensive insights from internal or external data sources, enrich rate-making processes, and gain access to advanced actuarial expertise. By leveraging modern technology from Akur8 and industry proficiency from Xceedance, insurers can realize immediate and tangible improvements in operational performance. Benefits to insurers include increased rate-making process efficiency, faster time-to-market, and enhanced governance and compliance in the rating process, as well as top-line and bottom-line growth potential.

“Akur8 is excited to join forces with Xceedance, a leading and recognized expert in the actuarial services landscape,” said Samuel Falmagne, CEO at Akur8. “By combining our resources, we can deliver a strong actuarial value proposition to insurance organizations — leveraging our unique ratemaking platform and top-notch actuarial expertise from Xceedance.”

The unique Akur8 insurance pricing platform leverages an innovative combination of proprietary machine learning (ML) algorithms and transparent artificial intelligence (AI) — which allows actuarial and predictive modelling teams to significantly increase speed-to-accuracy, without sacrificing auditability and control.

“The Akur8 platform is distinctive in the pricing landscape, with an innovative approach to incorporating data science in the ratemaking process,” said Matthew Duke, chief actuary, head of global actuarial and analytics services at Xceedance. “Automation of critical steps in the predictive modelling process significantly reduces time-to-market, while maintaining high levels of precision and transparency. The Akur8 solution, combined with actuarial and analytics services from Xceedance, creates a powerful offering for insurance organizations worldwide.”

Technology enablement is a key focus for the Xceedance actuarial and analytics services team. By combining its offerings with strategic partnerships globally, Xceedance supplies a comprehensive suite of technology-driven solutions to insurers and reinsurers of all sizes. Companies with actuarial and analytics infrastructure can benefit from a streamlined deployment, while organizations with limited resources can access those solutions via advisory and consulting services from Xceedance.

About Akur8
Akur8 is transforming insurance pricing with Transparent AI. Our proprietary ML algorithms automate rate making while preserving control and transparency throughout the process. We replace the manual processes of legacy solutions and the need to build and maintain large codebases through custom R/Python developments, while maintaining an output that is understandable & auditable, unlike black-box ML.

About Xceedance
Xceedance is a global provider of strategic consulting and managed services, technology, and data sciences to insurance organizations. The company helps insurers launch products, drive operations, implement intelligent technology, deploy advanced analytics, and achieve business process optimization. The experienced insurance professionals at Xceedance enable insurers worldwide to enhance policyholder service, enter new markets, boost workflow productivity, and improve profitability.

Media Contacts:

Astrid Noel (for Akur8)
+33 (0)7 68 24 93 27
[email protected]

Jennifer Overhulse, St. Nick Media (for Xceedance)
+1 859 803 6597
[email protected]

Latest News

U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy

SHANGHAI, China, Feb. 27, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. government has agreed to purchase a minimum of 100,000 doses of etesevimab (JS016 or LY-CoV016) 1400 mg and bamlanivimab (LY-CoV555) 700 […]

Bombardier Challenger 350 Jet Most Delivered in Category for Seventh Consecutive Year, Company Also Ends 2020 With Highest Total Market Share in Fourth Quarter

MONTREAL, Feb. 26, 2021 (GLOBE NEWSWIRE) — Bombardier announced today that its best-selling Challenger 350 aircraft was the most-delivered medium category business jet in 2020, making it the category leader for a seventh consecutive year. As detailed in the General Aviation Manufacturers Association’s (GAMA) annual shipment and billings report released February 24, the company also […]

Colliers ranked among top three commercial real estate brands by Lipsey survey

Ranking reaffirms Colliers’ commitment to leading the industry TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — For the fourth straight year, leading diversified professional services and investment management company Colliers (NASDAQ, TSX: CIGI) has been named one of the top three global commercial real estate brands by The Lipsey Company in its survey of industry professionals. […]